Business
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
—Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 —Streamlining operations and focusing on delivering potential value generating program milestones, with workforce reduction of approximately 20% and cost reductions expected to extend cash runway into 2027 —Second development candidate expected to be announced in 2025 —Ended first quarter 2025 with $139.0 million in cash, cash equivalents and marketab
About this update from Korro Bio, Inc.
[{"type":"image","alt":"Korro Bio, Inc.","displaySize":"","headline":null,"caption":"Korro Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/f88b50aee0d9d18bb284f79f2692388e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rSREgeXHJL6TSO0VlFoJTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f88b50aee0d9d18bb284f79f2692388e","width":300,"height":56}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"style":"text-align:center;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"—","length":1,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025","length":145,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"—","length":1,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Streamlining operations and focusing on delivering potential value generating program milestones, with workforce reduction of approximately 20% and cost reductions expected to extend cash runway into 2027","length":204,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"—","length":1,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[...